Is the Aviva share price a FTSE 100 bargain or a value trap?

Royston Wild examines whether FTSE 100 (INDEXFTSE: UKX) giant Aviva plc (LON: AV) could be the big-cap beauty you’ve been looking for.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

There are plenty of bona fide bargains strewn across the FTSE 100 index that can be picked up today. And going by the numbers alone, Aviva (LSE: AV) would be considered by some as falling into that category.

Thanks to City predictions of a 63% profits rise in 2018, the insurance giant carries a forward P/E of 9.4 times, inside the accepted bargain territory of 10 times or below. And what’s more, this stunning earnings projection also results in a corresponding sub-1 PEG reading of 0.1.

But is Aviva a genuine value star or a simple value trap waiting to trip you up?

Profits pounding higher

The Square Mile’s many analysts do not expect this year’s predicted rise to be the end of the matter and they are anticipating another 7% profits rise in 2019.

It’s easy to see why the experts are predicting sustained profit progression at Aviva. Last year the company’s market share grab in its core UK market helped revenues to keep driving through the roof. And the long-term structural opportunities created by solid economic growth, a rapidly-ageing population, and changing regulatory requirements provide plenty of scope for profits to keep rising.

These factors are not confined to its home marketplace either. Indeed, Aviva reported that profits leapt by double-digit percentages across three-quarters of its eight major territories in 2017.

What’s more, I am also pretty excited over the war chest it has for earnings-boosting M&A action in the near term and beyond. Indeed, it has recently earmarked £500m (which includes the £100m dedicated to the takeover of Ireland’s Friends First) for the pursuit of bolt-on acquisitions in its white-hot geographies.

Stunning yields

Arguably Aviva’s strongest pull is the promise of monster dividend yields, however.

The Footsie firm has almost doubled dividends over the past five years and brokers are predicting extra growth in the medium term at least. Last year’s 27.4p per share reward is anticipated to leap again to 29p in 2018, and then to 32.4p next year.

As a consequence, yields clock in at an eye-popping 5.4% and 6% for 2018 and 2019 respectively.

Indeed, with Aviva throwing up so much cash, it is also rewarding its shareholders by embarking on a massive share buyback scheme. The company plans to buy a maximum of £600m worth of shares and launched the operation at the turn of the month.

Now Aviva isn’t without its share of risk, of course. As my fellow Foolish writer Rupert Hargreaves pointed out recently, the firm almost followed the dinosaurs into extinction when the last financial crisis hit. And there are many signals flashing in the global economy that, despite the huge restructuring that has taken place since then, would unquestionably see the insurer come under huge strain yet again.

Having said that, I reckon these factors are more than baked into the FTSE 100 giant’s dirt-cheap earnings multiple. In my opinion it is a terrific blue-chip to buy today.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young Caucasian man making doubtful face at camera
Investing Articles

Surprise! This monopoly stock has taken over my Stocks and Shares ISA (again)

Our writer has a (nice) dilemma in his Stocks and Shares ISA portfolio after one incredible growth stock rocketed higher…

Read more »

Investing Articles

10.5% yield – but could the abrdn share price get even cheaper?

Christopher Ruane sees some things to like about the current abrdn share price. But will that be enough to overcome…

Read more »

Investing Articles

£9,000 to invest? These 3 high-yield shares could deliver a £657 annual passive income

The high yields on these dividend shares sail sit well above the FTSE 100 average of 3.6%. Here's why I…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

I’ve got £2k and I’m on the hunt for cheap shares to buy in December

Harvey Jones finally has some cash in his trading account and is hunting for cheap shares to buy next month.…

Read more »

Investing Articles

Down 25% with a 4.32% yield and P/E of 8.6! Is this my best second income stock or worst?

Harvey Jones bought GSK shares hoping to bag a solid second income stream while nailing down steady share price growth…

Read more »

Investing Articles

Here’s how the Legal & General dividend yield could ultimately hit 15%!

The Legal & General dividend yield is already among the best of any FTSE 100 share. Christopher Ruane explores some…

Read more »

Investing Articles

Is December a good time for me to buy UK shares?

This writer is weighing up which shares to buy for his portfolio next month, and one household name from the…

Read more »

Investing Articles

Is it time to dump my Lloyds shares and never look back?

Harvey Jones was chuffed with his Lloyds shares but recent events have made him rethink his entire decision to go…

Read more »